Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company...
February 25, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis...
February 24, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for...
February 15, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials...
January 24, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a...
January 05, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th...
January 04, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been...
December 14, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination...
December 14, 2021 07:15 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug...
December 13, 2021 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating...